Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October

Summary

EMA's Pharmacovigilance Risk Assessment Committee held its monthly meeting from September 28 to October 1, 2026, to review medicine safety assessments and safety signal evaluations. This is a routine regulatory activity with no specific drug approvals, clinical trial results, or company-specific announcements.